Biotech company BioInvent plans to start clinical development of TB-403 for the treatment of pediatric cancer along with the Belgian biopharmabolaget Thrombogenics.
A phase II/IIa program with TB-403 in patients with medulloblastoma is scheduled to start during the second half of the year 2015, BioInvent writes in a press release. BioInvent contributes half of the development costs and is entitled to 40 percent of all future income from the project.
Medulloblastoma is a rare, life-threatening form of cancer that affects children and youth exclusively.
Life Sience Sweden